Upfront Briefing
Ten years in, Moderna and Merck finally have the randomised Phase III that personalised cancer vaccines were always promised to deliver: intismeran autogene plus Keytruda beat Keytruda alone on recurrence-free survival in 1,137 patients with fully resected melanoma. Hazard ratios are being held back for a medical meeting, which is the biotech equivalent of "trust us, it's good." The FDA spent the same session handing out firsts — Ultragenyx's GENGLYCOS in glycogen storage disease Ia, priority review voucher included, and Regeneron's Pasatru in FOP, capping a three-decade hunt. Both are four-figure patient populations. Both are the only thing their patients have. Not a bad day's work for an agency that still does not have a confirmed commissioner.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,708.0 |
0.2% |
12.6% |
| Nasdaq 100 |
29,426.0 |
(0.2%) |
16.7% |
| Russell 2000 |
3,032.9 |
0.5% |
22.2% |
| Healthcare (XLV) |
175.7 |
3.5% |
13.0% |
| Biotech (XBI) |
169.6 |
5.9% |
39.5% |
| Nasdaq Biotech (NBI) |
7,404.9 |
6.4% |
29.8% |
| Clinical Trials (BBC) |
56.0 |
4.1% |
48.9% |
|
- Biotech went risk-on behind a single printout: XBI added 5.90% and NBI 6.39% after Moderna closed up 176.97% at $174.38 on the intismeran Phase III, lifting market cap from roughly $25B to $69B, with BioNTech up 21.96% on platform read-through. XLV's 3.51% was broader than one name — Merck's 12.60% move to $152.20 explains only about 60bp of it.
- The broader tape snapped a three-day losing streak on Treasury plumbing rather than growth: the Treasury said on 19 August it would more than double its buybacks of long-dated debt, sending TLT up 1.67% while the 10-year backed up three basis points to 4.67% — a flattener, not a rally. The S&P added 0.21% and the Nasdaq 100 fell 0.22% as megacap tech lagged; July FOMC minutes landed at 2pm ET.
- Market data: U.S. cash close Wednesday, 19 August 2026.
The Big 3
|
1
|
Moderna, Merck land the first Phase III win for a personalised cancer vaccine
|
- Moderna and Merck said intismeran autogene plus Keytruda met the primary endpoint of recurrence-free survival and the key secondary of distant metastasis-free survival in INTerpath-001, a 1,137-patient Phase III in fully resected stage IIB—IV melanoma; hazard ratios were not disclosed and will come at a medical meeting.
- Why it matters: First randomised Phase III win for any individualised neoantigen therapy, and the market treated it as a platform result rather than a melanoma result: Moderna closed up 176.97% at $174.38, lifting market cap from about $25B to $69B, with BioNTech up 21.96% on read-through to its own INT programme. Merck gets the post-Keytruda lifecycle story it needs ahead of the 2028 patent cliff. The caution is that topline is all anyone has — no hazard ratios, no confidence intervals, no overall survival — against a pre-readout consensus of 1 Buy, 12 Hold, 2 Sell and a $48.92 average target. Personalised manufacturing economics, not efficacy, is the gating item on peak sales.
- Source: STAT
- More: BioCentury; BioSpace; Fierce Biotech
|
|
2
|
Ultragenyx wins its first gene therapy approval — and a priority review voucher
|
- The FDA granted accelerated approval to GENGLYCOS (pariglasgene brecaparvovec-opnr, formerly DTX401) for glycogen storage disease type Ia in patients eight and older — Ultragenyx's first gene therapy clearance and fifth FDA approval — with a priority review voucher issued alongside it.
- Why it matters: Accelerated approval on a surrogate: the 48-week Phase III GlucoGene study (n=46) showed treated patients needed significantly less daily cornstarch than placebo, and confirmatory work is still owed. The base is 1,500—2,500 US patients and 6,000—8,000 worldwide, so this is a voucher-and-validation story rather than a revenue story, and the PRV is separately saleable to a peer. The bigger read is manufacturing: the July 2025 CRL on UX111 was CMC, not clinical, and this clearance says Bedford now passes inspection ahead of the 19 September UX111 PDUFA in Sanfilippo A. Shares added 6—14% after hours on thin volume.
- Source: Ultragenyx
- More: Reuters; Investing.com
|
| 3 | FDA clears Regeneron's Pasatru, the first-ever therapy for FOP |
- The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva, on the strength of the 63-patient Phase III OPTIMA trial.
- Why it matters: OPTIMA produced the kind of effect size that makes an ultra-rare label straightforward: at 56 weeks new HO lesions fell roughly 90% at 10 mg/kg (2 vs 19) and 94% at 3 mg/kg (1 vs 19) against placebo. The addressable population is about 900 diagnosed patients worldwide, so Pasatru will not move Regeneron's P&L against Eylea and Dupixent. What it does is clear a binary and validate activin A — the ligand Regeneron's own scientists identified as the driver of HO — as a druggable target. It also lands while Regeneron sits on an $18B cash pile and takes flak for not deploying it. Home infusion is permitted, which matters in a largely wheelchair-bound population.
- Source: STAT
- More: Pharmacy Times; Regeneron
|
Everything Else that broke
- Trump formally nominated Heidi Overton for FDA commissioner; Senator Bill Cassidy immediately flagged strong concerns about her lack of experience running a large organisation. — Endpoints
- Lilly's imminent mid-stage weight-loss readout is sharpening the debate over amylin agonist design and dosing schedules. — Endpoints
- Gene-editing specialists reviewing HuidaGene's ASGCT presentation split sharply on the science behind HG302, the CRISPR Duchenne programme in which a patient died. — STAT
- Capricor's deramiocel study design is facing fresh scrutiny. — STAT
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Lupin and Tenpoint partnered to commercialize YUVEZZI across Europe and select non-EU markets. — PR
- Essity is buying Kenvue's Brazil feminine care business for $284M. — PR
- Piramal Pharma closed the purchase of an incremental 40.67% of Yapan Bio for $7.95M, lifting it to 74% and converting the Hyderabad CDMO into a subsidiary. — PR
- Ovid struck a soticlestat milestone deal worth up to $295M. — BioWorld
- Amgen is exiting its TScan Crohn's collaboration, previously pegged at over $500M. — Fierce Biotech
- Tolerance Bio licensed NeoImmuneTech's long-acting IL-7 fusion protein efineptakin alfa for thymus-related indications in the Americas and Europe — equity consideration plus up to $260M in development and sales milestones and tiered royalties, with Phase 2 planned in HIV immunological non-response. — Fierce Biotech
VC / Private Financings
- Pixelgen closed an oversubscribed $15.5M Series B led by new investor Aescap Life Sciences, with participation from existing backers Navigare Ventures, AMF Tjänstepension and private investors, to expand its platform globally. — PR
IPOs / Follow-Ons
- No notable IPOs / follow-ons in the last 24 hours. — BioBucks
Academic Corner - Survodutide Once Weekly for the Treatment of Adults with Obesity. — NEJM
- Intramyocardial injection of allogeneic human induced pluripotent stem cell-derived cardiomyocytes in advanced ischemic heart failure: an early-stage randomized trial. — Nature Medicine
- Large-scale AI-guided liver malignancy diagnosis: multicenter study and a single-arm trial. — Nature Medicine
- Arginine Therapy for Sickle Cell Disease Acute Pain Episodes. — JAMA
|
